Denosumab biosimilar (Mabwell)

地舒单抗生物类似药（迈威）

Report date: 2024/04/16 15:56:21

Base Information

Drug NameDenosumab biosimilar (Mabwell)
Drug Alias Name重组全人源抗RANKL单抗注射液（江苏泰康生物医药）Denosumab biosimilar (Jiangsu T-mab BioPharma)Recombinant human anti-RANKL antibody (Jiangsu T-mab BioPharma)地诺单抗生物仿制药（江苏泰康生物医药）Prolia® biosimilar +[24] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanBiologics > Biosimilar
Mechanisms of ActionTumor necrosis factor ligand superfamily member 11 inhibitors
TargetsTumor necrosis factor ligand superfamily member 11
Therapy Area/IndicationsBone metastasesSolid tumoursOsteoporosis, Postmenopausal +[7] 
Global Approved IndicationsOsteoporosis, Postmenopausal
Approved Indications in ChinaOsteoporosis, Postmenopausal
Original Approved Country/TerritoryMainland China
Original Approved Date2023/03/28
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesJiangsu T-Mab Bio-Pharmaceuticals Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesJiangsu T-Mab Bio-Pharmaceuticals Co LtdSearleBinnopharm Group LLC +[4] 
Inactive CompaniesN/A
Active IndicationsBone metastasesSolid tumoursOsteoporosis, Postmenopausal +[4] 
Inactive IndicationsOsteoporosisBreast NeoplasmsBone Neoplasms

Other Information

ATC CodeM05BX04
Related LinksN/A